Ascendis Pharma A/S Ordinary Share (ASND)
Stock · NASDAQ · Health Care
$225.25as of 10/16/2026
Price chart
Active signals
Resistance level
$236.3
Industry
Biotechnology: Pharmaceutical Preparations
ASND Signal Track Record
How signals performed across all stocks →What ASND's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +4.5% | 64% | September 1, 2026 |
| Bollinger Band Breakout | 27 | -2.1% | 41% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +2.5% | 57% | September 18, 2026 |
| Bollinger Band Breakdown | 12 | +11.0% | 83% | September 15, 2026 |
| Any 20-session window (baseline) | +1.9% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,189
- Website
- ascendispharma.dk/
Fundamentals
- 1-day range
- $223.78$226.63
- Market cap
- $15.49B
- P/E (trailing)
- 16.93
- P/E (forward)
- 20.89
- EPS (trailing)
- $11.03
- Dividend yield
- —
- Beta
- 0.38
- Avg. volume
- 679.4K
52-week range
$186.05$282.15
Next earnings: April 30, 2026 · EPS estimate $0.43After Closeconfirmed
Forecasts
21 analyst ratings
Buy 96%
Hold 4%
Sell 0%
1-year price forecast
High
$350.85
+55.8%
Median
$305.23
+35.5%
Low
$262.96
+16.7%
Ascendis Pharma A/S Ordinary Share Competitors
Chosen by industry and closest market cap.
- ASNDAscendis Pharma A/S Ordinary Share$225.25▼ 0.60%Market cap $15.49BP/E 16.93$186.05$282.15
- BBIOBridgeBio Pharma Inc. Common Stock$66.39▼ 1.10%Market cap $16.20BP/E —$52.75$93.42
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$210.23▼ 1.95%Market cap $16.66BP/E 14.90$128.8$266.38
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S Ordinary Share | $15.49B | 16.93 | $225.25 | ▼ 0.60% | $186.05$282.15 |
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $66.39 | ▼ 1.10% | $52.75$93.42 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 14.90 | $210.23 | ▼ 1.95% | $128.8$266.38 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasiabenzinga · 10/16/2026
- FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingYahoo · 10/7/2026
- Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026Yahoo · 10/6/2026
- This Biotech’s Proprietary Platform Could Unlock Its Next Growth PhaseYahoo · 10/5/2026
- Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth TodayBenzinga · 9/30/2026
- BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation DismissedBenzinga · 9/30/2026
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeekingAlpha · 9/24/2026
- Ascendis Pharma (ASND) Authorizes $400M Share BuybackYahoo · 9/21/2026
- Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic ProgramsYahoo · 9/19/2026
Insider Activity
Insider Actions →Acquired
15.0K
Disposed
31.9K
- Bodenhoff Mads · September 8, 2026 · Option Exercise3.0K @ $110
- Bodenhoff Mads · September 8, 2026 · Sale3.0K @ $270.19
- HOLTUG LARS · September 2, 2026 · Sale236 @ $264.13
- Jean Jacques Bienaime · August 14, 2026 · Buy900 @ $246.91
- Jean Jacques Bienaime · August 14, 2026 · Buy1.1K @ $245.85
- Scott Thomas Smith · June 2, 2026 · Buy100 @ $219
- Scott Thomas Smith · May 29, 2026 · Buy250 @ $223.32
- Jean Jacques Bienaime · May 29, 2026 · Buy100 @ $223.5
- Jean Jacques Bienaime · May 29, 2026 · Buy200 @ $223.76
- Jean Jacques Bienaime · May 26, 2026 · Buy200 @ $236.24
- Flemming Steen Jensen · May 11, 2026 · Sale19.5K @ $238.49
- Jean Jacques Bienaime · April 14, 2026 · Grant9.2K
- Jean Jacques Bienaime · April 14, 2026 · Disposition9.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Ascendis Pharma signs BioMarin license deal, ends litigation
Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.
Ascendis Pharma signs BioMarin license deal, ends litigation. Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.